ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Sterilization failure rates compared with long-acting reversible contraceptives

Sterilization failure rates compared with long-acting reversible contraceptives
Contraceptive method Pregnancies per 1000 procedures (follow-up interval in years)
1 to 2 years 3 to 5 years 7 to 12 years
Female permanent contraception
Postpartum permanent contraception
Postpartum partial salpingectomy 1.2 (1) 6.3 (5) 7.5 (10)
Postpartum titanium clips (Filshie clips) 17 (2)
Interval permanent contraception
Interval partial salpingectomy 7.3 (1) 15.1 (5) 20.1 (10)
Interval titanium clips (Filshie clips) 4 (2)
Silicone rubber band (Falope Ring) 3 (1 to 2) 10 (5) 17.7 (10)
Electrosurgery 3.2* (5)
Male permanent contraception
Vasectomy 1.5 (2)
LARC
LNG IUD 52/8 (Mirena/LilettaΔ) 2 (1) 7 (5) 14 (8)
LNG IUD 19.5/5 (Kyleena)§ 2 (1) 15 (5)
LNG IUD 13.5/3 (Skyla)¥ 4 (1) 9 (3)
TCu380A copper IUD (Paragard) 8 (1) 14 (7); 22 (12)
Etonogestrel implant (Nexplanon) 0.5 (1) 4 (3); 6 (5)

LARC: long-acting reversible contraception; LNG: levonorgestrel; IUD: intrauterine device.

* With three contiguous sites of fulguration along the fallopian tube (a total length of fulguration of approximately 3 cm).

¶ LNG-releasing IUD containing 52 mg LNG at initial placement and with an initial LNG release rate of 20 mcg/day for 8 years (Mirena).

Δ LNG-releasing IUD containing 52 mg LNG at initial placement and with an initial LNG release rate of 18.6 mcg/day for 8 years (Liletta).

◊ 5-year data is 7/1000 for Mirena and 8/1000 for Liletta; this is not statistically different.

§ LNG-releasing IUD containing 19.5 mg LNG at initial placement and with an initial LNG release rate of 17.5 mcg/day, which declines to 7.4 mcg/day at 5 years (Kyleena).

¥ LNG-releasing IUD containing 13.5 mg LNG at initial placement and with an initial LNG release rate of 14 mcg/day for 3 years (Skyla).
References:
  1. Peterson HB, Xia Z, Hughes JM, et al. The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization. Am J Obstet Gynecol 1996; 174:1161.
  2. Peterson HB, Xia Z, Wilcox LS, et al. Pregnancy after tubal sterilization with bipolar electrocoagulation. U.S. Collaborative Review of Sterilization Working Group. Obstet Gynecol 1999; 94:163.
  3. Rodriguez MI, Edelman AB, Kapp N. Postpartum sterilization with the titanium clip: a systematic review. Obstet Gynecol 2011; 118:143.
  4. Lawrie TA, Kulier R, Nardin JM. Techniques for the interruption of tubal patency for female sterilization. Cochrane Database Syst Rev 2015; 9:CD003034.
  5. Hatcher RA, Trussell J, Nelson AL, et al. Contraceptive Technology, 20th ed, Ardent Media, Inc, New York 2011.
  6. Eisenberg DL, Schreiber CA, Turok DK, et al. Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system. Contraception 2015; 92:10.
  7. Nelson A, Apter D, Hauck B, et al. Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial. Obstet Gynecol 2013; 122:1205.
  8. Sivin I, Stern J, Cutinho E, et. al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380Ag IUDs. Contraception 1991; 44:473.
  9. Bayer Pharmaceuticals. https://hcp.kyleena-us.com/about-kyleena/efficacy/ (Accessed on November 01, 2018).
  10. Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C. Contraception 1997; 56:341.
  11. Jensen JT, Lukkari-Lax E, Schulze A, et al. Contraceptive efficacy and safety of the 52-mg levonorgestrel intrauterine system for up to 8 years: findings from the Mirena Extension Trial. Am J Obstet Gynecol 2022; 227:873.e1.
  12. Creinin MD, Schreiber CA, Turok DK, et al. Levonorgestrel 52 mg intrauterine system efficacy and safety through 8 years of use. Am J Obstet Gynecol 2022; 227:871.e1.
Graphic 54215 Version 10.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟